It is the second leading cause of malignancy deaths in the United States. Colorectal cancer begins as a noncancerous, benign polyp or development in the glands in the lining of the colon or rectum and progresses to cancerous, malignant tumors. Risks for colon cancer include being over the age of 60, being of African American or Eastern European descent, having a diet high in red or processed meats and having a family history of colon cancer. Having cancer elsewhere in the body, including an individual history of breast tumor, having colorectal polyps or an inflammatory bowel disease can easily raise the risk also.Gideon Steinbach, M.D., Ph.D., is slated to end up being the main investigator of the Cequent trial. Dr. Steinbach is usually associate professor of medicine at the University of Washington, and served as the PI of a prior celecoxib FAP Phase II trial that established a high regular for polyposis trials. The upcoming Stage I FAP trial will provide as a proof of concept for Cequent’s tkRNAi technology, regarding to Mr. Parker. ‘We believe our technology offers an elegant option to the RNAi delivery issue which has stymied significant improvement in the field to day. We modify live, non-pathogenic bacteria in a proprietary procedure to create and deposit mediators of RNAi directly into the prospective cells.
Next Post: Cardiac Technology receives U.